Introduction
============

Gene amplification at chromosome 17q (Chr17q) involves the human epidermal growth factor receptor 2 (*HER2*) gene and is observed in about 15% to 20% of breast cancers. *HER2*amplification is associated with aggressive tumor behavior (increased metastatic potential and reduced survival), and it also predicts a patient\'s response to trastuzumab therapy \[[@B1],[@B2]\]. Although HER2-positive breast cancers are classified as a tumor subgroup, they are quite heterogeneous. Indeed, they can be divided more or less equally into hormone receptor-negative (estrogen receptor/progesterone receptor-negative, or ER/PR-negative) and hormone receptor-positive (ER/PR-positive) tumors. In the ER/PR-positive subgroup, development of resistance to antihormonal therapy could be explained by the cross-talk between the HER2 and ER pathways \[[@B3]\]. Furthermore, first-line treatment of HER2-positive breast cancers with trastuzumab presents response rates that vary between 25% and 35%, and the benefit of trastuzumab therapy has been shown only in patients with high levels of *HER2*amplification \[[@B4]\]. Comparative genomic hybridization arrays and fluorescence *in situ*hybridization (FISH) studies have shown that HER2-amplified breast cancers present a variety of alterations on Chr17 and gene amplifications at Chr17q12-q21 are particularly frequent and complex \[[@B5]\]. Among the genes that are located in this region and have been reported to be amplified in breast cancers, topoisomerase IIα (*TOP2A*), a gene coding for the enzyme targeted by anthracyclines, is located 2 Mb from *HER2*. *TOP2A*amplification might be linked to the sensitivity to anthracyclines observed in HER2-positive breast tumors \[[@B6]-[@B18]\]. Most of the published data indicate that *TOP2A*amplification occurs only in HER2-amplified tumors. However, some authors have reported cases in which *TOP2A*was amplified also in the absence of *HER2*amplification \[[@B19],[@B20]\]. Interestingly, the same studies do not support the role of *TOP2A*amplification as a predictive marker for response to anthracyclines. These works also report a different frequency of *TOP2A*amplifications and deletions. The presence of *TOP2A*deletions, often analyzed together with *TOP2A*amplification, has complicated the question of the relations among *TOP2A*alteration, prognosis and response to anthracyclines. Technical issues, the cutoff levels used to classify a gene as amplified or deleted and different quality assurance guidelines could also explain these discrepancies \[[@B21],[@B22]\].

Nevertheless, the molecular variations within the Chr17q amplicon and their clinical implications remain largely unknown. Indeed, besides *TOP2A*, other genes which are located not only in the *HER2*smallest region of amplification (SRA) \[[@B23],[@B24]\] but also all along the long arm of the Chr17 \[[@B5],[@B24]-[@B27]\] might also be amplified, and they could play functional roles in breast cancer development and progression. To explore this hypothesis, we carried out a quantitative analysis of a set of 11 genes that were chosen for their localization along Chr17q12-q21 and for their putative role in breast cancer development. Two genes were located on the centromeric side (*MED1*and *STARD3*), and nine were located on the distal side (*GRB7*, *THRA*, *RARA*, *TOP2A*, *IGFBP4*, *CCR7*, *KRT20*, *KRT19*and *GAS*) of Ch17q12-21 relative to *HER2*localization. The relation between gene amplification and patients\' characteristics and survival was then analyzed. We show that amplification of *TOP2A*and of other genes distal to *HER2*does not occur in tumors in which *HER2*is not amplified. We confirm that *TOP2A*is not included in the SRA involving *HER2*and describe different copy number alterations along the distal side of Chr17q. We also show that *TOP2A*nonamplification is related to worse survival in the subpopulation patients with of ER/PR-negative tumors.

Materials and methods
=====================

Patients\' characteristics, tumor samples and treatment
-------------------------------------------------------

A total of 759 consecutive breast cancer patients referred to the Val d\'Aurelle Cancer Center between March 2002 and May 2005 were prospectively entered into the database of a tumor DNA bank. Ethical approval was provided by the local research ethics committee. All patients gave their written, informed consent. The DNA bank was created using frozen, histologically proven invasive breast cancer specimens that were primarily handled for ER testing by the dextran charcoal method. Patients with primary HER2-positive breast cancer were initially selected on the basis of the level of HER2 expression by immunohistochemistry (IHC) using the HercepTest (DakoCytomation, Trappes, France). HER2 scores of 0 and 1 were considered negative. HER2 scores of 2+ were then checked by FISH for *HER2*copy number (PathVysion HER-2 *DNA*Probe Kit; Abbott Molecular, Rungis, France). Only patients with HER2 scores of 3+ derived by IHC or positive for *HER2*amplification by FISH were considered HER2-positive. *HER2*copy number and Chr17 polysomy were then assessed by quantitative polymerase chain reaction (qPCR) as previously described \[[@B28]\]. Patients presenting with Chr17 polysomy without true *HER2*amplification were excluded from the study. Adjuvant treatment was discussed in multidisciplinary medical meetings according to local and international guidelines and submitted for each patient\'s approval. All patients were treated at least by adjuvant radiation therapy and received anthracycline-based adjuvant therapy according to the medical standards at the time of diagnosis. Considering the patient accrual period, and despite their HER2-positive status, women were not treated with adjuvant anti-HER2 therapy, with the exception of patients included in a clinical trial to assess the benefits of trastuzumab as adjuvant therapy. The clinicopathologic characteristics and treatments are summarized in Table [1](#T1){ref-type="table"}. Patients received regular follow-up examinations, that is, every 6 months for the first 5 years, then yearly after that.

###### 

Patients\' characteristics^a^

  --------------------------------------------------------
  Characteristic                 Number of patients (%)\
                                 (*n* = 86)
  ------------------------------ -------------------------
  Age, yr                        

   \<50                          33 (38.4%)

   ≥50                           53 (61.6%)

  T                              

   1                             35 (40.7%)

   2                             46 (53.5%)

   3                             4 (4.6%)

   4                             1 (1.2%)

  N                              

   N^+^                          51 (59.3%)

   N^-^                          35 (40.7%)

  SBR                            

   2                             36 (42.3%)

   3                             49 (57.7%)

   Missing                       1

  Hormone receptor status        

   ER                            

    ER^-^                        60 (69.8%)

    ER^+^                        26 (30.2%)

   PR                            

    PR^-^                        44 (51.2%)

    PR^+^                        42 (48.8%)

   ER/PR                         

    ER^-^/PR^-^                  42 (48.9%)

    ER^-^/PR^+^                  18 (20.9%)

    ER^+^/PR^-^                  2 (2.3%)

    ER^+^/PR^+^                  24 (27.9%)

  Treatment                      

   Chemotherapy                  

    Anthracyclines               42 (48.8%)

    Anthracyclines and taxanes   26 (30.2%)

    No chemotherapy              18 (21.0%)

   Radiation therapy             86 (100.0%)

   Antihormone therapy           34 (39.5%)

   Trastuzumab                   20 (23.3%)

  Outcomes                       

    Recurrence                   25 (29.1%)

    Death                        17 (20.0%)
  --------------------------------------------------------

^a^T, tumor size; N, lymph node status; SBR, Scarff-Bloom-Richardson histological grade; ER, estrogen receptor; PR, progesterone receptor.

DNA extraction and gene quantification
--------------------------------------

Each frozen tumor specimen was pulverized in liquid nitrogen with an automatic grinder (Cryobroyeur 2000P Automatique; Rivoire, Montpellier, France), homogenized in a Polytron homogenizer in buffer (20 mM Tris HCI, 1.5 mM ethylenediaminetetraacetic acid (EDTA), 10 mM Na~2~MoO~4~, 1.5 mM dithiothreitol and 10% glycerol, pH 7.4) (buffer:tissue ratio was 10:1 (vol/wt)) used for ER and PR measurement and centrifuged at 10,000 × *g*for 15 minutes. Total genomic DNA was extracted from the pellet. The DNA concentration was determined by measuring the absorbance at 260 nm, and all samples had a 260/280-nm ratio higher than 1.7. DNA was stored at -20°C in TE buffer (10 mM Tris and 0.5 mM EDTA, pH 7.6). All procedures were carried out at 4°C unless noted otherwise. qPCR amplifications were performed with 10 ng of DNA on a Rotorgene 6000 apparatus (Qiagen, Courtaboeuf, France) using ABsolute Blue qPCR SYBR Green Mix (ref AB-4167; ThermoFisher Scientific, Illkirch, France) with an initial 15-minute denaturation step at 95°C followed by 40 cycles. The cycling temperatures and the primers used for each gene are summarized in Table [2](#T2){ref-type="table"}. After completion of the amplification, samples were subjected to a temperature ramp (from the annealing temperature to 95°C with a transition rate of 0.1°C/s) with continuous fluorescence monitoring for melting curve analysis. *MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20*, *KRT19*and *GAS*amplification levels were normalized to those of the somatostatin receptor type II (*SSTR2*) gene that is localized on Chr17q24. *HER2*quantification was also normalized to the expression values of glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*), which is localized on chromosome 12p13, and of β-actin (*ACBT*), which is localized on chromosome 7p22, as controls for polysomy. *SSTR2*quantification was also normalized to *GAPDH*and *ACBT*to detect *SSTR2*amplification. Quantification was obtained by constructing a standard curve from serial dilutions of normal genomic DNA (ref 11 691 112 001; Roche, Meylan, France). For *HER2*amplification, genomic DNA from SKBR3 cells was used as a positive control and DNA from MCF-7 cells was used as a negative control. Water was used as a negative control for PCR contamination. A gene was considered to be amplified when the target gene-to-reference gene ratio was ≥2, and it was considered to be deleted when the target gene-to-reference gene ratio was ≤0.5.

###### 

Primer sequences and qPCR conditions used to quantify *MED1, STARD3, HER2, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20, KRT19, GAS, ACBT, GAPDH*and *SSTR2*^a^

  -----------------------------------------------------------------------------------------------------------------------------------------------
  GenBank accession number   Gene name/primer    Sequence 5\'-3\'                        Size\   GC, %   **Amplicon**,\   Annealing temperature
                                                                                         nt              bp               
  -------------------------- ------------------- --------------------------------------- ------- ------- ---------------- -----------------------
  [NP_004765](NP_004765)     *MED1*sense         ATT CTC CTG GGC TTC TCC AA              20      50%     97               54°C

                             *MED1*antisense     CCA CAC ACC AGG GAG TCA TT              20      55%                      

  [NP_006795](NP_006795)     *STARD3*sense       CAG GCT GCT AGG GTG TAA CTG             21      57%     114              64°C

                             *STARD3*antisense   GAC AGA GCA CCG GAG AAC AG              20      60%                      

  [NM_004448](NM_004448)     *HER2*sense         GCT CCC CAT ATG TCT CCC G               19      63%     101              58°C

                             *HER2*antisense     CCG GAC ATG GTC TAA GAG GC              20      60%                      

  [NP_005301](NP_005301)     *GRB7*sense         CTC TGG CTC AGA ACT TCC TGA AT          23      48%     142              60°C

                             *GRB7*antisense     GTG CCC TTG GTG GAG TAA TAG AG          23      52%                      

  [NP_003241](NP_003241)     *THRA*sense         GTG GAC AAG ATC GAG AAG AGT CAG         24      50%     119              60°C

                             *THRA*antisense     AGG TCA GTC ACC TTC ATC AGC AG          23      52%                      

  [NP_000955](NP_000955)     *RARA*sense         GGA GTG CTC AGA GTG GGT TC              20      60%     110              64°C

                             *RARA*antisense     AGA AGG TCA TGG TGT CCT GCT C           22      55%                      

  [NP_001058](NP_001058)     *TOP2A*sense        GAT TCT GGA CCA ACC TTC AAC TA          23      43%     121              58°C

                             *TOP2A*antisense    ATG TAC CAT CCT ACT ATC AAC TCA CTT T   28      36%                      

  [NP_001543](NP_001543)     *IGFBP4*sense       CTC TTC CGG TGC TGA CCT CT              20      60%     146              60°C

                             *IGFBP4*antisense   GGT GCT CCG GTC TCG AAT                 18      61%                      

  [NP_001829](NP_001829)     *CCR7*sense         AGG CTA AAT CCC AGC CAG AG              20      55%     127              58°C

                             *CCR7*antisense     CTG TGG TGT TGT CTC CGA TG              20      55%                      

  [XP_352920](XP_352920)     *KRT20*sense        ATG GCT TCA GAA GGA CCA GTT             21      48%     95               56°C

                             *KRT20*antisense    TGG AGA TCA GCT TCC ACT GTT A           22      45%                      

  [NP_002267](NP_002267)     *KRT19*sense        TGA CAT GCG AAG CCA ATA TG              20      45%     124              56°C

                             *KRT19*antisense    AAA GCC CTC CCC TTC CTA AC              20      55%                      

  [X00183](X00183)           *GAS*sense          TCT CCC CAG ACT GGC TCT GA              20      60%     146              64°C

                             *GAS*antisense      GCC GAA GTC CAT CCA TCC AT              20      55%                      

  [NP_001041](NP_001041)     *SSTR2*sense        GCC TCC AGG GTC CAT TAA GG              20      60%     101              60°C

                             *SSTR2*antisense    ATT GAG TGG CTC ATC CGC C               19      58%                      

  [NP_001092](NP_001092)     *ACBT*sense         CCA CAC TGT GCC CAT CTA CG              20      60%     99               65°C

                             *ACBT*antisense     AGG ATC TTC ATG AGG TAG TCA GTC AG      26      46%                      

  [NT_009759](NT_009759)     *GAPDH*sense        CTC ACG TAT TCC CCC AGG TT              20      55%     161              58°C

                             *GAPDH*antisense    CCC AAA GCA CAT TTC TTC CA              20      45%                      
  -----------------------------------------------------------------------------------------------------------------------------------------------

^a^qPCR, quantitative polymerase chain reaction; *MED1*, mediator complex subunit 1 gene; *STARD3*, steroidogenic acute regulatory-related lipid transfer (START) domain containing 3 gene; *HER2*, human epidermal growth factor receptor 2 gene; *GRB7*, growth factor receptor-bound protein 7 gene; *THRA*, thyroid hormone receptor α gene; *RARA*, retinoic acid receptor α gene; *TOP2A*, topoisomerase IIα gene; *IGFBP4*, insulin-like growth factor-binding protein 4 gene; *CCR7*, C-C chemokine receptor type 7 gene; *KRT20*, cytokeratin 20 gene; *KRT19*, cytokeratin 19 gene; *GAS*, gastrin gene; *ACBT*, β-actin gene; *GAPDH*, glyceraldehyde 3-phosphate dehydrogenase gene; *SSTR2*, somatostatin receptor type II gene.

Statistical analysis
--------------------

Categorical variables were described using frequency distributions, and continuous variables were stated using medians and ranges. Correlations between genes was evaluated using the Spearman\'s ρ correlation. Association between categorical variables was assessed with the χ^2^test (or Fisher\'s exact test when appropriate). Differences were considered statistically significant when *P*\< 0.05. Survival rates were estimated from the date of surgery to the date of the event of interest using the Kaplan-Meier method. The median survival was calculated with 95% confidence interval (95% CI). For overall survival (OS), the event of interest was death, regardless of the cause. Patients lost to follow-up were censored at the last documented visit. For relapse-free survival (RFS), the event of interest was recurrence. Patients who were alive at the last follow-up examination and without recurrence were censored at the time of the last follow-up examination. Patients who died without recurrence were censored at the date of death. Differences in survival rates were compared using a log-rank test. Statistical analyses were performed with Stata 10.0 software (Stata Corp., College Station, TX, USA).

Results
=======

Description of the study population
-----------------------------------

Eighty-six patients with HER2-amplified breast cancer were included in the study. The median follow-up period was 55 months (range, 6 to 81 months). A total of 25 patients (29%) relapsed after a median of 18 months from the date of surgery (range, 2 to 71 months), and 17 patients (20%) died after a median of 31 months (range, 6 to 78 months). The 5-year RFS rate was 69% (95% CI, 57% to 78%) and the 5-year OS rate was 79% (95% CI, 67% to 87%). There were no statistical associations between RFS or OS and the adjuvant treatment administered. The distribution of tumors relative to their pattern of amplified and nonamplified genes was homogeneous in the different treatment groups.

Analysis of the Chr17q12-q21 amplicon by qPCR
---------------------------------------------

The variability in the efficiency of each parameter was between 92% and 105% with a standard deviation of 0.04. The reference genes (*SSTR2*, *GAPDH*and *ACBT*) were chosen in regions previously described as presenting a low level of instability or amplification \[[@B25],[@B26]\] and were controlled together to detect amplification. Their crossing point values were 19.2 ± 0.56, 18.7 ± 0.47 and 17.6 ± 0.43, respectively. The absence of *SSTR2*amplification was confirmed in all samples by measuring the *SSTR2*:*GAPDH*and *SSTR2*:*ACBT*ratios, which in all cases were \<1.5. Finally, none of the 40 HER2-negative cancer specimens (negative controls) showed amplification of the studied genes. The status (amplified, deleted or normal) of the 11 genes (*MED1, STARD3, GRB7, THRA, RARA, TOP2A, IGFBP4, CCR7, KRT20*, *KRT19*and *GAS*) evaluated in the 86 HER2-positive cancer samples is summarized in Table [3](#T3){ref-type="table"}. Coamplification with *HER2*occurred in 65.1% of samples for *MED1*(56 of 86), 93% for *STARD3*(80 of 86), 97.7% for *GRB7*(84 of 86), 54.7% for *THRA*(47 of 86), 26.7% for *RARA*(23 of 86), 26.7% for *TOP2A*(23 of 86), 20.9% for *IGFBP4*(18 of 86), 20.9% for *CCR7*(18 of 86), 14% for *KRT20*(12 of 86), 11.6% for *KRT19*(10 of 86) and 7% for *GAS*(6 of 86). *HER2*presented the highest level of amplification (mean, 6.4; range, 2 to 32), whereas the frequency of amplification of the other genes decreased according to the distance of the gene from *HER2*(Figure [1](#F1){ref-type="fig"}). The amplification levels of *HER2*and of the other genes were compared by linear regression analysis. *HER2*amplification levels were correlated only with the amplification levels of *MED1*(ρ = 0.84), *STARD3*(ρ = 0.87) and *GRB7*(ρ = 0.93), but not of other genes, particularly *TOP2A*(ρ = 0.65). Gene deletions occurred in fewer than 5.8% of the samples, regardless of the gene studied (Table [3](#T3){ref-type="table"}).

###### 

Gene amplification quantification relative to the *SSTR2*reference gene^a^

  --------------------------------------------------------------
  Gene             Number of patients (%)\   Median (range)
                   (*n*= 86)                 
  ---------------- ------------------------- -------------------
  *MED1*                                     

   Deletion        3 (3.5%)                  0.5 (0.5 to 0.5)

   Normal          27 (31.4%)                0.9 (0.6 to 1.9)

   Amplification   56 (65.1%)                4.6 (2 to 27.8)

   Total           86 (100.0%)               2.6 (0.5 to 27.8)

  *STARD3*                                   

   Deletion        0                         \-

   Normal          6 (7.0%)                  1.5 (0.7 to 1.9)

   Amplification   80 (93.0%)                6.4 (2.0 to 74.9)

   Total           86 (100.0%)               5.9 (0.7 to 74.9)

  *HER2*                                     

   Amplification   86 (100.0%)               6.4 (2 to 32)

  *GRB7*                                     

   Deletion        0                         \-

   Normal          2 (2.3%)                  1.1 (0.6 to 1.7)

   Amplification   84 (97.7%)                6.8 (2.3 to 36.5)

   Total           86 (100.0%)               6.6 (0.6 to 36.5)

  *THRA*                                     

   Deletion        1 (1.2%)                  0.5

   Normal          38 (44.2%)                1.1 (0.6 to 1.9)

   Amplification   47 (54.7%)                4.4 (2.0 to 11.7)

   Total           86 (100.0%)               2.2 (0.5 to 11.7)

  *RARA*                                     

   Deletion        3 (3.5%)                  0.5 (0.4 to 0.5)

   Normal          60 (69.8%)                1.0 (0.6 to 1.9)

   Amplification   23 (26.7%)                3.4 (2.0 to 11.1)

   Total           86 (100.0%)               1.1 (0.4 to 11.1)

  *TOP2A*                                    

   Deletion        4 (4.7%)                  0.5 (0.5 to 0.5)

   Normal          59 (68.6%)                1.0 (0.6 to 1.8)

   Amplification   23 (26.7%)                3.2 (2 to 7)

   Total           86 (100.0%)               1.1 (0.5 to 7)

  *IGFBP4*                                   

   Deletion        5 (5.8%)                  0.5 (0.5 to 0.5)

   Normal          63 (73.3%)                1.0 (0.6 to 1.9)

   Amplification   18 (20.9%)                3.1 (2 to 8)

   Total           86 (100.0%)               1.1 (0.5 to 8)

  *CCR7*                                     

   Deletion        3 (3.5%)                  0.4 (0.4 to 0.5)

   Normal          65 (75.6%)                0.9 (0.6 to 1.8)

   Amplification   18 (20.9%)                3.3 (2 to 14.9)

   Total           86 (100.0%)               1.0 (0.4 to 14.9)

  *KRT20*                                    

   Deletion        2 (2.3%)                  0.5 (0.5 to 0.5)

   Normal          72 (83.7%)                1.1 (0.6 to 1.8)

   Amplification   12 (14.0%)                3.1 (2.3 to 11.6)

   Total           86 (100.0%)               1.1 (0.5 to 11.6)

  *KRT19*                                    

   Deletion        5 (5.8%)                  0.5 (0.5 to 0.5)

   Normal          71 (82.6%)                1.0 (0.6 to 1.8)

   Amplification   10 (11.6%)                3.0 (2 to 6.4)

   Total           86 (100.0%)               1.0 (0.5 to 6.4)

  *GAS*                                      

   Deletion        2 (2.3%)                  0.5 (0.4 to 0.5)

   Normal          78 (90.7%)                1.0 (0.6 to 1.7)

   Amplification   6 (7.0%)                  2.8 (2 to 14.4)

   Total           86 (100.0%)               1.0 (0.4 to 14.4)
  --------------------------------------------------------------

^a^Amplification: target gene/*SSTR2*ratio ≥2; deletion: target gene/*SSTR2*ratio ≤0.5; normal: 0.5 \< target gene/*SSTR2*ratio \<2. *MED1*, mediator complex subunit 1 gene; *STARD3*, steroidogenic acute regulatory-related lipid transfer (START) domain containing 3 gene; *HER2*, human epidermal growth factor receptor 2 gene; *GRB7*, growth factor receptor-bound protein 7 gene; *THRA*, thyroid hormone receptor α gene; *RARA*, retinoic acid receptor α gene; *TOP2A*, topoisomerase IIα gene; *IGFBP4*, insulin-like growth factor-binding protein 4 gene; *CCR7*, C-C chemokine receptor type 7 gene; *KRT20*, cytokeratin 20 gene; *KRT19*, cytokeratin 19 gene; *GAS*, gastrin gene; *SSTR2*, somatostatin receptor type II gene.

![**Gene amplification distribution on chromosome 17q12-q21 in Human epidermal growth factor receptor 2 (HER2)-positive breast cancer specimens on the basis of the overview of chromosome 17 with the National Center for Biotechnology Information\'s Sequence Viewer version 2.9 database**\[[@B55]\]. The frequency of amplification (percentage of positive breast cancer specimens on the *y*-axis) for a gene decreases with the increase of its distance from HER2. *MED1*, mediator complex subunit 1 gene; *STARD3*, steroidogenic acute regulatory-related lipid transfer (START) domain containing 3 gene; *HER2*, human epidermal growth factor receptor 2 gene; *GRB7*, growth factor receptor-bound protein 7 gene; *THRA*, thyroid hormone receptor α gene; *RARA*, retinoic acid receptor α gene; *TOP2A*, topoisomerase IIα gene; *IGFBP4*, insulin-like growth factor-binding protein 4 gene; *CCR7*, C-C chemokine receptor type 7 gene; *KRT20*, cytokeratin 20 gene; *KRT19*, cytokeratin 19 gene; *GAS*, gastrin gene.](bcr2824-1){#F1}

Relation between the pattern of gene amplification and clinical characteristics
-------------------------------------------------------------------------------

Node status (N), Scarff-Bloom-Richardson histological (SBR) grade and ER/PR-negative status were significantly associated with worse outcomes in terms of both RFS rate (*P*= 0.007, *P*= 0.004 and *P*= 0.024, respectively) and OS rate (*P*= 0.020, *P*= 0.048 and *P*= 0.076, respectively) (univariate analysis) (see Table [4](#T4){ref-type="table"} and Figure [2](#F2){ref-type="fig"} for ER/PR status). The patterns of gene amplification were not significantly correlated with the T or SBR grade. Conversely, *MED1*amplification tended to be associated with ER-positive tumors (*P*= 0.072), whereas amplification of *RARA*, *KRT20*or *KRT19*was significantly associated with node-positive breast cancers (*P*= 0.030, *P*= 0.002 and *P*= 0.033, respectively). Moreover, patients with TOP2A-amplified tumors tended to have better RFS rates (hazard ratio (HR) = 0.47, 95% CI 0.16 to 1.38, *P*= 0.159) and OS rates (HR = 0.34, 95% CI 0.08 to 1.48, *P*= 0.132) than patients with TOP2A nonamplified tumors (Figure [2](#F2){ref-type="fig"}). The subgroup of patients with ER/PR-negative cancers without amplification of *TOP2A*in particular had the worst RFS rates (HR = 0.29, 95% CI 0.13 to 0.65, *P*= 0.001) and the worst OS rates (HR = 0.28, 95% CI 0.10 to 0.76, *P*= 0.008).

###### 

Univariate analysis of the different variables^a^

                                      RFS            OS                                               
  ------------------------------ ---- -------------- -------------- --------------------- ---- ------ ---------------------
  T                                                                                                   
   1                             35   8              74.2           1                     6    84.2   1
   2                             46   15             65.9           1.51 (0.64 to 3.58)   10   74.3   1.30 (0.47 to 3.60)
   3 or 4                        5    2              53.3           2.15 (0.45 to 10.4)   1    80.0   1.34 (0.16 to 11.3)
                                      *P*= 0.510\*   *P*= 0.868\*                                     
  N                                                                                                   
   N^-^                          35   4              88.1           1                     2    94.2   1
   N^+^                          51   21             55.8           3.94 (1.35 to 11.5)   15   70.0   4.89 (1.12 to 21.4)
                                      *P*= 0.007\*   *P*= 0.020\*                                     
  SBR                                                                                                 
   2                             36   5              84.9           1                     4    89.4   1
   3                             49   20             55.8           3.80 (1.42 to 10.2)   13   70.8   2.96 (0.96 to 9.15)
                                      *P*= 0.004\*   *P*= 0.048\*                                     
  ER                                                                                                  
   ER^-^                         60   19             66.9           1                     13   76.2   1
   ER^+^                         26   6              70.1           0.64 (0.25 to 1.60)   4    84.9   0.68 (0.22 to 2.10)
                                      *P*= 0.333\*   *P*= 0.505\*                                     
  PR                                                                                                  
   PR^-^                         44   18             57.6           1                     13   67.3   1
   PR^+^                         42   7              80.9           0.36 (0.15 to 0.87)   4    92.4   0.32 (0.10 to 0.99)
                                      *P*= 0.018\*   *P*= 0.037\*                                     
  ER/PR                                                                                               
   ER^-^/PR^-^                   42   17             58.7           1                     12   68.9   1
   Other                         44   8              78.2           0.39 (0.17 to 0.91)   5    89.2   0.40 (0.14 to 1.14)
                                      *P*= 0.024\*   *P*= 0.076\*                                     
  *MED1*                                                                                              
   Del/Nm                        30   10             66.2           1                     7    72.9   1
   Amp                           56   15             70.0           0.76 (0.34 to 1.70)   10   82.5   0.63 (0.23 to 1.69)
                                      *P*= 0.507\*   *P*= 0.354\*                                     
  *STARD3*                                                                                            
   Del/Nm                        6    2              55.6           1                     2    53.3   1
   Amp                           80   23             69.4           0.85 (0.20 to 3.62)   15   80.9   0.48 (0.11 to 2.14)
                                      *P*= 0.826\*   *P*= 0.327\*                                     
  *GRB7*                                                                                              
   Del/Nm                        2    1              50.0           1                     1    0.00   1
   Amp                           84   24             69.3           0.30 (0.04 to 2.33)   16   80.1   0.15 (0.02 to 1.20)
                                      *P*= 0.225\*   *P*= 0.038\*                                     
  *THRA*                                                                                              
   Del/Nm                        39   16             59.0           1                     11   73.8   1
   Amp                           47   9              79.3           0.50 (0.22 to 1.13)   6    84.7   0.53 (0.19 to 1.43)
                                      *P*= 0.090\*   *P*= 0.199\*                                     
  *RARA*                                                                                              
   Del/Nm                        63   21             64.1           1                     15   75.2   1
   Amp                           23   4              82.4           0.50 (0.17 to 1.45)   2    91.3   0.36 (0.08 to 1.59)
                                      *P*= 0.190\*   *P*= 0.162\*                                     
  *TOP2A*                                                                                             
   Del/Nm                        63   21             63.7           1                     15   74.8   1
   Amp                           23   4              82.4           0.47 (0.16 to 1.38)   2    91.3   0.34 (0.08 to 1.48)
                                      *P*= 0.159\*   *P*= 0.132\*                                     
  *IGFBP4*                                                                                            
   Del/Nm                        68   21             66.6           1                     15   76.9   1
   Amp                           18   4              77.4           0.70 (0.24 to 2.06)   2    88.9   0.49 (0.11 to 2.16)
                                      *P*= 0.520\*   *P*= 0.335\*                                     
  *CCR7*                                                                                              
   Del/Nm                        68   21             67.0           1                     16   75.3   1
   Amp                           18   4              75.4           0.66 (0.22 to 1.93)   1    94.4   0.21 (0.03 to 1.61)
                                      *P*= 0.442\*   *P*= 0.099\*                                     
  *KRT20*                                                                                             
   Del/Nm                        74   21             69.2           1                     15   78.8   1
   Amp                           12   4              66.7           1.31 (0.45 to 3.81)   2    81.5   1.02 (0.23 to 4.49)
                                      *P*= 0.622\*   *P*= 0.981\*                                     
  *KRT19*                                                                                             
   Del/Nm                        76   23             67.6           1                     16   78.3   1
   Amp                           10   2              78.7           0.70 (0.16 to 2.96)   1    90.0   0.64 (0.08 to 4.82)
                                      *P*= 0.624\*   *P*= 0.658\*                                     
  *GAS*                                                                                               
   Del/Nm                        80   24             68.0           1                     16   79.1   1
   Amp                           6    1              83.3           0.64 (0.09 to 4.74)   1    83.3   1.21 (0.16 to 9.20)
                                      *P*= 0.660\*   *P*= 0.852\*                                     
                                                                                                      
  ER^-^/PR^-^and *TOP2A*Del/Nm   30   15             49.2           1                     11   61.0   1
  Others                         56   10             79.2           0.29 (0.13 to 0.65)   6    89.7   0.28 (0.10 to 0.76)
                                      *P*= 0.001\*   *P*= 0.008\*                                     

^a^T, tumor size; N, lymph node status; SBR grade, Scarff-Bloom-Richardson histological grade; ER, estrogen receptor; PR, progesterone receptor; Del, deletion; Nm, normal; Amp, amplification; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; *MED1*, mediator complex subunit 1 gene; *STARD3*, steroidogenic acute regulatory-related lipid transfer (START) domain containing 3 gene; *HER2*, human epidermal growth factor receptor 2 gene; *GRB7*, growth factor receptor-bound protein 7 gene; *THRA*, thyroid hormone receptor α gene; *RARA*, retinoic acid receptor α gene; *TOP2A*, topoisomerase IIα gene; *IGFBP4*, insulin-like growth factor-binding protein 4 gene; *CCR7*, C-C chemokine receptor type 7 gene; *KRT20*, cytokeratin 20 gene; *KRT19*, cytokeratin 19 gene; *GAS*, gastrin gene; *SSTR2*, somatostatin receptor type II gene; \*log-rank test.

![**Kaplan-Meier curves for relapse-free survival (RFS) and overall survival (OS)**. **(a)**Estrogen receptor/progesterone receptor (ER/PR) status. Blue line indicates ER- and PR-negative (ER^-^/PR^-^) status; black line indicates ER-, PR- or ER/PR-positive (ER^-^/PR^+^, ER^+^/PR^-^or ER^+^/PR^+^) status. **(b)**Topoisomerase IIα (*TOP2A*) amplification. Blue line indicates deleted or nonamplified (normal) *TOP2A*(TOP2A Del/N); black line indicates amplified *TOP2A*(TOP2A Amp). For RFS, *P*= 0.159; for OS, *P*= 0.132. **(c)***TOP2A*and ER/PR status. Blue line indicates ER- and PR-negative (ER^-^/PR^-^) and deleted or nonamplified *TOP2A*(TOP2A Del/N); black line indicates ER-, PR-, or ER/PR-positive (ER^-^/PR^+^, ER^+^/PR^-^and ER^+^/PR^+^) status and amplified *TOP2A*(TOP2A Amp). For RFS, *P*= 0.001; for OS, *P*= 0.008.](bcr2824-2){#F2}

Discussion
==========

In this work, we quantified gene amplification in the 17q12 to 17q21 region around *HER2*in HER2-amplified breast tumors. Among the patients with primary breast cancer, fewer than 12% had HER2-positive tumors. This result is in accordance with recent studies reporting 12% to 15% of *HER2*amplification compared to the 20% to 25% found in historical studies \[[@B29],[@B30]\], in which Chr17 polysomy may have led to discordant interpretations between higher signals due to polysomy and those due to an absolute increase of *HER2*gene copy number in a significant proportion of cases \[[@B31]\]. Gene amplification on the centromeric side (*MED1*and *STARD3*) and the distal side (*GRB7*, *THRA*, *RARA*, *TOP2A*, *IGFBP4*, *CCR7*, *KRT20*, *KRT19*and *GAS*) relative to *HER2*localization on Chr17q was determined by qPCR, an efficient method for performing copy number analysis \[[@B32]\], and with reference genes located on Chr17 (*SSTR2*) and Chr4 and Chr2 (*GAPDH*and *ACBT*, respectively) to differentiate polysomy from true amplification. In fact, tumors presenting only Chr17 polysomy should not be considered as HER2-amplified, and patients with this presentation might not benefit from anti-HER2 therapy, although these tumors present moderate HER2 overexpression \[[@B28],[@B33]\], but only as a result of treatment with anthracyclines \[[@B34]\].

We have confirmed that gene amplification, including that of *TOP2A*, occurs only in patients with HER2-amplified breast tumors. We then showed that *HER2*presents the highest amplification value and that the frequency of amplification of a gene decreases with its distance from *HER2*. These results suggest that instability within Chr17q is driven by *HER2*amplification. Indeed, HER2-positive tumors have higher levels of overall genomic instability than HER2-negative tumors, supporting the idea that *HER2*amplification is the key amplicon driver on Chr17q \[[@B35],[@B36]\]. Moreover, we found a correlation between the amplification levels of *HER2*and that of *MED1*, STARD3 and GRB7, but not of *TOP2A*and the other genes localized on the distal side of Chr17q. Therefore, the SRA of *HER2*seems to be limited to a small number of genes, among which are *STARD3*and *GRB7*as described by Katoh *et al.*\[[@B37]\] and as recently reported by Beroukhim *et al.*\[[@B38]\] in different cancer types. Kuwahara *et al.*\[[@B39]\] identified a region between *HER2*and *GRB7*(a gene located 47 kb from *HER2*) that contains a recombinant hot spot for amplification, deletion and translocation. This site might be located between *GRB7*and *THRA*, a gene located 315 kb from *GRB7*, given that 84 (97.7%) of the cancer specimens we assessed presented GRB7 amplification, whereas only 47 (54.7%) showed *THRA*amplification. The presence of this hot spot might explain why the frequency of recombination for a gene is higher when it is located closer to *HER2*and gradually decreases for genes located far away from *HER2*. In general, the gene amplification architectures derived from our results illustrate the complexity of the rearrangement mechanisms (sister chromatid breakage-fusion-bridge cycles, formation and reinsertion of double minutes and repeated units at a single locus) and highlight the diversity of HER2-amplified cancers \[[@B40],[@B41]\].

Finally, we found a low overall number of deletions (\<5.8%), regardless of the gene analyzed. For *TOP2A*, the deletion rate was 4.7%, which is low compared with values found in other studies (between 8.1% and 35%) \[[@B22]\]. This might be explained by the fact that in heterogenic tumors, which simultaneously present amplifications and deletions, qPCR cannot detect deletions that are present in a very small number of cells. It is also possible that in certain studies the percentage of tumors with deletions was overestimated as a result of poor standardization of the FISH technique. Indeed, Di Leo *et al.*\[[@B42],[@B43]\] recently showed high interlaboratory variations for *TOP2A*quantification, whereas Press *et al.*\[[@B44]\] found a deletion rate comparable to ours in a prospective study using standardized FISH.

We then investigated the clinical impact of Chr17 anomalies. Amplification of *RARA*, *KRT20*and *KRT19*correlated with node invasion, suggesting that tumors with amplification of genes on the distal side of Chr17q are more aggressive than tumors with amplifications restricted to the SRA of *HER2*. *MED1*amplification showed a tendency to be associated with ER-positive tumors. *MED1*encodes the mediator complex subunit 1 (MED1) \[[@B45]\] that anchors mediator to ERβ \[[@B46]\] while also interacting with ERα \[[@B47]\]. Although our study did not show any significant impact of *MED1*amplification on survival, the prognostic value of *MED1*should nevertheless be evaluated in a larger ER/PR-positive population. Similarly, *TOP2A*amplification was not a statistically significant prognostic factor, but patients with tumors in which *TOP2A*was amplified tended to have better RFS and OS rates (see Figure [2b](#F2){ref-type="fig"}). This result is in accord with a recent study in which patients with HER2-positive, TOP2A-amplified cancers presented a trend of better survival than patients with HER2-positive breast cancers with deleted or normal *TOP2A*\[[@B48]\]. Conversely, the subgroup of patients with ER/PR-negative breast cancers and nonamplified (normal or deleted) *TOP2A*showed the least favorable RFS and OS rates in our population. We could not determine whether the prognosis was even less favorable in the case of ER/PR-negative tumors with TOP2A-deleted status than of tumors with normal *TOP2A*. Nevertheless, *TOP2A*deletions, which are often heterozygous \[[@B49]\], do not result in total loss of expression of the protein \[[@B50]\]. Their unfavorable prognosis might be explained by the fact that ER/PR-negative, TOP2A nonamplified tumors may not be responsive to hormone therapy and/or to anthracycline-based therapy because of the absence or insufficient number of targets. Adjuvant therapy would thus not be beneficial for these patients. Indeed, recent findings suggest that the presence of *TOP2A*deletions is not associated with better chemosensitivity or response to anthracyclines, while the occurrence of *TOP2A*amplifications may identify a subgroup of patients with increased response to anthracyclines \[[@B18],[@B44]\]. Many studies have been conducted on the impact of the presence of *HER2*and *TOP2A*amplifications on survival and response to chemotherapy. Only a few studies found that there was no benefit to treating patients with HER2-positive cancer with anthracyclines or that *TOP2A*amplification had no predictive value. The subject remains controversial \[[@B51]\], but nevertheless two large trials (the National Surgical Adjuvant Breast and Bowel Project B-11 and the National Cancer Institute of Canada MA.5 studies) have retrospectively shown a correlation between *HER2*amplification and benefit from adjuvant anthracycline-based chemotherapy \[[@B52],[@B53]\]. Moreover, a pooled analysis that included 8 studies and 1,536 HER2-positive patients indicated that anthracyclines were superior to non-anthracycline-based regimens in terms of disease-free and overall survival \[[@B54]\].

Conclusions
===========

Few studies have used qPCR to assess gene copy number alterations in HER2-amplified breast cancer. The assay we have developed can be used to assess the amplification status of multiple genes. We have shown that *MED1*, *STARD3*, *TOP2A*, *GRB7*, *THRA*, *RARA*, *IGFBP4*, *CCR7*, *KRT19*, *KRT20*and *GAS*amplification occurred only in HER2-amplified breast cancers with variable frequencies. We have confirmed that *HER2*seems to drive genomic instability along Chr17q and that *TOP2A*was not included in the SRA of *HER2*. The different patterns of amplification we observed suggest complex amplification mechanisms leading to a variety of subtypes. *RARA*, *KRT19*and *KRT20*amplification could be related to a more invasive breast cancer profile. Moreover, we confirm the clinical importance of identifying the subgroup of patients with ER/PR-negative, TOP2A nonamplified cancer, as they have the worst prognosis. A prospective study including a larger number of patients treated with trastuzumab and anthracycline-based adjuvant therapy would be useful to determine the predictive value of *TOP2A*amplification and the prognostic value of gene copy number variations along Chr17q.
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